Fujian University of Traditional Chinese Medicine, Fujian, China.
The preferential metastasis of cancer cells to skeleton not only disrupts the process of bone remodeling and influences the therapeutic decision, but also results in severe complications. Although the current diagnosis of bone metastases (BM) relies on bone imaging techniques, they are not sensitive enough for early detection as well as they are invasive and expensive to use. Since factors derived from bone metabolism are potentially useful to diagnose metastatic bone disease in cancer patients, a number of clinical trials have been carried out on this area. Results suggest that higher levels of bone biomarkers are associated with an increased risk of BM. As a result, biochemical-markers are showing prospects in early diagnosis of BM. This review summarizes the available evidence on the clinical use of biochemical-markers in the diagnosis of various cancers with high incidence of BM including breast, prostate and lung.
Written by:
Huang Q, Ouyang X. Are you the author?
Reference: Cancer Epidemiol. 2011 Apr 5. Epub ahead of print.
doi: 10.1016/j.canep.2011.02.001
PubMed Abstract
PMID: 21474411
UroToday.com Prostate Cancer Section
